Fate Therapeutics Inc
$ 1.97
5.35%
11 Jun - close price
- Market Cap 229,622,000 USD
- Current Price $ 1.97
- High / Low $ 1.99 / 1.82
- Stock P/E N/A
- Book Value 1.55
- EPS -1.09
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.56 %
- 52 Week High 2.88
- 52 Week Low 0.91
About
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.
Analyst Target Price
$5.41
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-02-26 | 2025-11-13 | 2025-08-12 | 2025-05-13 | 2025-03-05 | 2024-11-12 | 2024-08-13 | 2024-05-09 | 2024-02-26 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 | -0.4 | -0.33 | -0.47 | -0.45 | -0.46 | -0.54 |
| Estimated EPS | -0.28 | -0.274 | -0.28 | -0.34 | -0.38 | -0.4238 | -0.41 | -0.45 | -0.45 | -0.52 | -0.56 | -0.58 |
| Surprise | 0.02 | 0.004 | 0.01 | 0.05 | 0.06 | -0.0162 | 0.01 | 0.12 | -0.02 | 0.07 | 0.1 | 0.04 |
| Surprise Percentage | 7.1429% | 1.4599% | 3.5714% | 14.7059% | 15.7895% | -3.8226% | 2.439% | 26.6667% | -4.4444% | 13.4615% | 17.8571% | 6.8966% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FATE
2026-06-10 18:10:40
H.C. Wainwright has reiterated a "Buy" rating and a $7.00 price target for Fate Therapeutics (FATE) following promising Phase 1 data for its lead cell therapy program, FT819, presented at the annual EULAR meeting. The data demonstrated a sustained clinical improvement in systemic lupus erythematosus patients with bendamustine conditioning and supported the upcoming Phase 2 RECLAIM-LN trial. Fate Therapeutics is a clinical-stage biopharmaceutical company focusing on immunotherapies for cancer and immune disorders.
2026-06-10 14:22:00
H.C. Wainwright reiterated a "Buy" rating and a $7.00 price target for Fate Therapeutics (FATE) after the company presented positive Phase 1 data for its lead off-the-shelf cell therapy program, FT819, at the annual EULAR meeting. The data demonstrated deeper and more consistent B-cell depletion in systemic lupus erythematosus patients, supporting the potential for outpatient administration and advancing to the Phase 2 RECLAIM-LN trial. Fate Therapeutics is a clinical-stage biopharmaceutical company focused on cellular immunotherapies for cancer and immune disorders.
2026-06-05 23:09:29
Piper Sandler has reiterated its Buy rating for Fate Therapeutics (FATE.US) and maintained a target price of $6. The firm's decision reflects continued confidence in the company's prospects. This analyst rating suggests that Piper Sandler sees significant upside potential for Fate Therapeutics stock.
2026-06-05 01:09:29
Fate Therapeutics presented promising clinical data on its off-the-shelf CAR T-cell therapy candidates, FT819 and FT839, at the European Congress of Rheumatology annual meeting. FT819 demonstrated rapid and sustained clinical improvement and a favorable tolerability profile in lupus patients, alongside effective B-cell depletion and reset. Preclinical data for FT839 showed comprehensive elimination of activated immune cells in rheumatoid arthritis patient samples without conditioning chemotherapy, indicating its potential for broad autoimmune disease treatment.
2026-06-05 00:39:34
Fate Therapeutics provided updates on its off-the-shelf cell therapy pipeline, highlighting data for FT819 in autoimmune diseases and FT836 in cancer. The company announced plans for a potentially registrational Phase 2 trial for FT819 in lupus nephritis, targeting 53 patients with enrollment beginning in late 2026. Financially, Fate Therapeutics reported a cash runway into 2028, supported by approximately $174.8 million in cash and a 20% reduction in operating expenses during Q1 2026.
2026-06-04 20:39:34
Fate Therapeutics (FATE) has released an updated corporate presentation ahead of EULAR 2026, detailing significant progress in its clinical programs. The update highlights positive safety and clinical improvements in the FT819 Phase 1 trial, with Phase 2 enrollment planned for the second half of 2026. Additionally, the FT836 pan–solid tumor Phase 1 study is actively enrolling, showing preliminary anti-tumor activity.
